论文部分内容阅读
目的观察联合应用多西他赛、奥沙利铂和替吉奥(DOS)新辅助化疗治疗进展期胃上部癌和胃下部癌的疗效。方法进展期胃癌患者72例分为胃上部癌(UGC组,29例)和胃下部癌(LGC组,43例)两组,均采用DOS方案新辅助化疗3个周期,4周后行标准D2手术,术后常规化疗。比较两组疗效和不良反应等相关指标。结果两组化疗不良反应发生率相仿(P>0.05),且多为Ⅰ、Ⅱ级反应,经对症治疗后均有所缓解;其不良反应主要为白细胞减少、血小板减少、食欲下降和恶心呕吐等。UGC组的临床有效率和疾病控制率均高于LGC组(82.8%vs.60.5%和100%vs.86.0%)(P<0.05)。两组患者1年生存率比较无统计学差异(82.6%vs.83.5%)(P>0.05)。结论DOS方案新辅助化疗治疗进展期胃上部癌的疗效较进展期胃下部癌更好。
Objective To observe the curative effect of combination of docetaxel, oxaliplatin and tegaserod (Neoadjuvant chemotherapy) on advanced gastric cancer and lower gastric cancer. Methods 72 patients with advanced gastric cancer were divided into two groups: upper gastric cancer (UGC group, 29 cases) and lower gastric cancer group (43 cases). Both groups were treated with neoadjuvant chemotherapy for 3 cycles by DOS regimen and standard D2 surgery 4 weeks later. Postoperative conventional chemotherapy. The curative effects and adverse reactions of the two groups were compared. Results The incidence of adverse reactions in the two groups were similar (P> 0.05), and mostly grade Ⅰ and Ⅱ responses were relieved after symptomatic treatment; the main adverse reactions were leukopenia, thrombocytopenia, loss of appetite and nausea and vomiting . The clinical effective rate and disease control rate of UGC group were higher than that of LGC group (82.8% vs.60.5% and 100% vs.86.0%, P <0.05). There was no significant difference in one-year survival rate between two groups (82.6% vs.83.5%) (P> 0.05). Conclusion DOS regimen neoadjuvant chemotherapy is superior to advanced gastric cancer in the treatment of advanced gastric cancer.